JP2013521304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013521304A5 JP2013521304A5 JP2012556213A JP2012556213A JP2013521304A5 JP 2013521304 A5 JP2013521304 A5 JP 2013521304A5 JP 2012556213 A JP2012556213 A JP 2012556213A JP 2012556213 A JP2012556213 A JP 2012556213A JP 2013521304 A5 JP2013521304 A5 JP 2013521304A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amount
- subject
- laquinimod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 29
- 229960004577 laquinimod Drugs 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 26
- 229960000485 methotrexate Drugs 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 14
- 229940109239 creatinine Drugs 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 230000000737 periodic effect Effects 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 201000001474 proteinuria Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 206010007710 Cartilage injury Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 2
- 241001111421 Pannus Species 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 238000009535 clinical urine test Methods 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 150000002344 gold compounds Chemical class 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 150000003873 salicylate salts Chemical class 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 2
- 229960001940 sulfasalazine Drugs 0.000 claims description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33937510P | 2010-03-03 | 2010-03-03 | |
| US61/339,375 | 2010-03-03 | ||
| PCT/US2011/026885 WO2011109531A1 (en) | 2010-03-03 | 2011-03-02 | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521304A JP2013521304A (ja) | 2013-06-10 |
| JP2013521304A5 true JP2013521304A5 (https=) | 2014-04-17 |
| JP5819328B2 JP5819328B2 (ja) | 2015-11-24 |
Family
ID=44531858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556213A Expired - Fee Related JP5819328B2 (ja) | 2010-03-03 | 2011-03-02 | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8501766B2 (https=) |
| EP (1) | EP2542079B1 (https=) |
| JP (1) | JP5819328B2 (https=) |
| KR (1) | KR20130014523A (https=) |
| CN (2) | CN102781240A (https=) |
| AU (1) | AU2011223697B2 (https=) |
| BR (1) | BR112012022187A2 (https=) |
| CA (1) | CA2791709A1 (https=) |
| CL (1) | CL2012002424A1 (https=) |
| CO (1) | CO6630085A2 (https=) |
| DK (1) | DK2542079T3 (https=) |
| EA (1) | EA201290860A1 (https=) |
| ES (1) | ES2476368T3 (https=) |
| MX (1) | MX2012010066A (https=) |
| NZ (1) | NZ602478A (https=) |
| PE (1) | PE20130690A1 (https=) |
| PH (1) | PH12012501740A1 (https=) |
| PT (1) | PT2542079E (https=) |
| SG (1) | SG183513A1 (https=) |
| SI (1) | SI2542079T1 (https=) |
| WO (1) | WO2011109531A1 (https=) |
| ZA (1) | ZA201207128B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| RS52169B (sr) | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| KR20110048571A (ko) * | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| RS54328B1 (sr) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| PT2467372T (pt) | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| CN102791130B (zh) * | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
| SG10201505236YA (en) | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| HK1220125A1 (zh) | 2013-03-14 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德的透皮配方 |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN115281149A (zh) * | 2021-05-12 | 2022-11-04 | 四川大学华西医院 | 一种临床前类风湿关节炎(Pre-RA)小鼠模型 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) * | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US6696407B1 (en) * | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| PL199781B1 (pl) * | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| US6852323B2 (en) * | 2000-07-21 | 2005-02-08 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| US6307050B1 (en) * | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) * | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US20070292461A1 (en) * | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| AR044927A1 (es) * | 2003-06-25 | 2005-10-12 | Elan Pharm Inc | Metodos y composiciones para tratar la artritis reumatoidea |
| US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| WO2005097162A2 (en) * | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and their use |
| US20090048181A1 (en) * | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| ZA200803327B (en) * | 2005-10-26 | 2009-09-30 | Serono Lab | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
| US20080108641A1 (en) * | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) * | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| ES2752137T3 (es) * | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| US8410115B2 (en) * | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| WO2007103112A2 (en) * | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US9399061B2 (en) * | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2007139887A2 (en) | 2006-05-22 | 2007-12-06 | Cargill, Incorporated | Methods for treating bone or joint inflammation |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| ATE510538T1 (de) * | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
| JP2010513518A (ja) | 2006-12-19 | 2010-04-30 | メリマック ファーマシューティカルズ インコーポレーティッド | 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法 |
| WO2008085484A2 (en) | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
| CA2970273C (en) * | 2007-07-11 | 2020-04-14 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| ES2445451T3 (es) * | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| KR20110048571A (ko) * | 2008-09-03 | 2011-05-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제 |
| JP2012508768A (ja) | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
| RS54328B1 (sr) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| NZ602512A (en) * | 2010-03-03 | 2014-07-25 | Teva Pharma | Treatment of lupus arthritis using laquinimod |
| CN102791130B (zh) * | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
| SG10201505236YA (en) * | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| EP3056205A1 (en) * | 2010-07-09 | 2016-08-17 | Teva Pharmaceutical Industries, Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| WO2012078591A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| WO2013016686A1 (en) | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
| EA201490377A1 (ru) | 2011-07-28 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата |
-
2011
- 2011-03-02 JP JP2012556213A patent/JP5819328B2/ja not_active Expired - Fee Related
- 2011-03-02 MX MX2012010066A patent/MX2012010066A/es active IP Right Grant
- 2011-03-02 EA EA201290860A patent/EA201290860A1/ru unknown
- 2011-03-02 PH PH1/2012/501740A patent/PH12012501740A1/en unknown
- 2011-03-02 CA CA2791709A patent/CA2791709A1/en not_active Abandoned
- 2011-03-02 CN CN2011800121091A patent/CN102781240A/zh active Pending
- 2011-03-02 BR BR112012022187A patent/BR112012022187A2/pt not_active IP Right Cessation
- 2011-03-02 DK DK11751300.2T patent/DK2542079T3/da active
- 2011-03-02 NZ NZ602478A patent/NZ602478A/en not_active IP Right Cessation
- 2011-03-02 PE PE2012001383A patent/PE20130690A1/es not_active Application Discontinuation
- 2011-03-02 ES ES11751300.2T patent/ES2476368T3/es active Active
- 2011-03-02 SG SG2012063491A patent/SG183513A1/en unknown
- 2011-03-02 CN CN201610240474.2A patent/CN105796556A/zh active Pending
- 2011-03-02 SI SI201130210T patent/SI2542079T1/sl unknown
- 2011-03-02 KR KR1020127025006A patent/KR20130014523A/ko not_active Ceased
- 2011-03-02 US US13/039,188 patent/US8501766B2/en not_active Expired - Fee Related
- 2011-03-02 PT PT117513002T patent/PT2542079E/pt unknown
- 2011-03-02 EP EP11751300.2A patent/EP2542079B1/en active Active
- 2011-03-02 AU AU2011223697A patent/AU2011223697B2/en not_active Ceased
- 2011-03-02 WO PCT/US2011/026885 patent/WO2011109531A1/en not_active Ceased
-
2012
- 2012-08-31 CL CL2012002424A patent/CL2012002424A1/es unknown
- 2012-09-17 CO CO12159942A patent/CO6630085A2/es unknown
- 2012-09-21 ZA ZA2012/07128A patent/ZA201207128B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521304A5 (https=) | ||
| ES3001196T3 (es) | Nuevo uso de una combinación de un bloqueador del receptor de la angiotensina (ARB) con un inhibidor de la endopeptidasa neutra (NEPI) | |
| US20250241919A1 (en) | Combination of active agents for the treatment of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) | |
| JP2010518122A5 (https=) | ||
| JP5753152B2 (ja) | アミロイドーシスを処置するための製剤および方法 | |
| JP2015512406A5 (https=) | ||
| JP2020508339A5 (https=) | ||
| JP2017537164A (ja) | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ | |
| JP2014532726A5 (https=) | ||
| Huddleston et al. | Emerging strategies for treating gout | |
| JP2019536816A (ja) | 高血圧の処置のための組成物 | |
| JP2020519576A5 (https=) | ||
| TW201330852A (zh) | 具有高度腎功能障礙之血栓栓塞症患者之血栓栓塞症之預防治療劑 | |
| TW201811372A (zh) | 利用fxr促效劑之方法 | |
| JP7696299B2 (ja) | Ｇａｐｄｈを阻害する方法及び組成物 | |
| TWI411435B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於治療脊髓創傷之用途 | |
| JP2017533967A (ja) | システアミン組成物を用いるハンチントン病の処置方法 | |
| WO2014141295A2 (en) | Treatment and prophylaxis of kidney diseases | |
| CN105358148A (zh) | 用于治疗肾小球疾病的losmapimod | |
| MX2011010030A (es) | Medicamento novedoso para el tratamiento del deterioro cognitivo. | |
| WO2011060162A1 (en) | Tivozanib and temsirolimus in combination | |
| AU2019204289B2 (en) | Methods and compositions for the treatment of pain and/or inflammation | |
| CZ2003234A3 (cs) | 2-Aryl-8-oxodihydropurinové deriváty jako léčivo | |
| CN116688135A (zh) | 一种骨关节炎药物治疗组合物及其制备方法和应用 | |
| WO2015028673A1 (en) | Cav3 CHANNEL BLOCKING AGENT FOR PAIN TREATMENT |